Last Updated : August 19, 2024
Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.
Input is information, insight, or advice given to us to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.
Draft Recommendations
pembrolizumab (Keytruda)
Therapeutic Area: Gastric or gastroesophageal junction (GEJ) adenocarcinoma
Draft recommendations posted for stakeholder feedback: September 5, 2024
End of feedback period: September 19, 2024
Draft Recommendation
ivosidenib (Tibsovo)
Therapeutic Area: Acute myeloid leukemia (AML)
Draft recommendations posted for stakeholder feedback: September 5, 2024
End of feedback period: September 19, 2024
Draft Recommendation
abemaciclib (Verzenio)
Therapeutic Area: Adjuvant treatment of HR-positive, HER2-negative early breast cancer
Draft recommendations posted for stakeholder feedback: September 5, 2024
End of feedback period: September 19, 2024
Draft Recommendation
osimertinib (Tagrisso)
Therapeutic Area: Non-small cell lung cancer
Draft recommendations posted for stakeholder feedback: September 5, 2024
End of feedback period: September 19, 2024
Draft Recommendation
Open Calls for Patient and Clinician Input
Therapeutic Area
Therapeutic Area:
multiple myeloma not eligible for ASCT
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Thyroid Eye Disease (TED), chronic
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Thyroid Eye Disease (TED), acute
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
B-cell precursor acute lymphoblastic leukemia
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Hidradenitis suppurative
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Ulcerative colitis
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Gynecological cancers
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Nonsegmental vitiligo
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Metastatic non-small cell lung cancer (NSCLC)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Endometrial cancer that is mismatch repair deficient (dMMR)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Last Updated : August 19, 2024